Molecular Profile | KRAS G13D |
Therapy | LY3009120 |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Create By | c-seddy |
Update By | c-seddy |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | KRAS G13D | colorectal cancer | sensitive | LY3009120 | Preclinical | Actionable | In a preclinical study, LY3009120 inhibited growth of, and blocked MAPK signaling in human colorectal cancer cells harboring KRAS G13D in culture (PMID: 26343583). | 26343583 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(26343583) | Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. | Full reference... |